Key Takeaways BIO unveils four new ddPCR systems, enhancing its Life Science offerings post-Stilla Technologies acquisition. BIO's new systems improve workflow, precision and throughput across PCR applications in key research areas. BIO sees strong adoption of ddPCR tools, aided by recent investments and platform expansions in 2024.Bio-Rad Laboratories (BIO) recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ...